CORE--DICATIONIC DRUGS AGAINST PNEUMOCYSTIS CARINII AND GIARDIA LAMBLIA

核心B继续主要负责测试新型芳香族化合物 阳离子分子，由Tidwell和Boykin合成用于活性 糖皮质激素抑制大鼠对卡氏肺炎性肺炎(PCP)的抑制作用 疾病的模型。将由核心执行的新研究将包括 Tidwell合成的前体药物代谢活性的体外分析 和Boykin，在体内测试它们的抗PCP活性之前。此外, 将启动有限数量的初步药代动力学研究 具有优异的抗五氯苯酚活性的选定化合物 大鼠模型的毒性最小(这些高级研究将得到资助 由企业赞助商制药生态公司提供)。最后，这个核心将继续 提供Dykstra在生化和分子研究中使用的生物体。

Core B continues to be responsible primarily for testing novel aromatic dicationic molecules, synthesized by Tidwell and Boykin for activity against P. carinii pneumonia (PCP) in the corticosteroid suppressed rat model of disease. New research to be performed by the core will include in vitro analysis of metabolic activation of prodrugs, synthesized by Tidwell and Boykin, prior to testing their anti-PCP activity in vivo. In addition, preliminary pharmacokinetic studies will be initiated for a limited number of selected compounds that exhibit excellent anti-PCP activity with minimal toxicity in the rat model (these advanced studies will be funded by the corporate sponsor, Pharm-Eco). Finally, this core will continue to supply organisms used in the biochemical and molecular studies by Dykstra.